Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05022446

Conditions

COVID-19 Infection

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Interventions

Survey Administration

Study Details

Brief summary:

This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.

Conditions

COVID-19 Infection

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Study ID

NCT05022446

Start date

Nov 11, 2020

Status verified date

Aug, 2026

Completion date

Feb 2, 2027

Anticipated

Primary completion date

Feb 2, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)
  • These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership

Exclusion Criteria:

None

Study Design

Enrollment

250 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (survey)

Participants complete survey over 5-10 minutes.

Interventions

Survey Administration

Complete survey

Primary outcome measure

  • To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic. [ Time Frame: through study completion, an average of 1 year ]
  • To evaluate the pulmonary medicine programs that adapted their provider staffing in response to the coronavirus-2019 (COVID-19) epidemic. [ Time Frame: through study completion, an average of 1 year ]
  • To evaluate the pulmonary medicine programs that adapted their techniques in response to the coronavirus-2019 (COVID-19) epidemic. [ Time Frame: through study completion, an average of 1 year ]
  • To evaluate the pulmonary medicine programs that adapted their ambulatory operations in response to the coronavirus-2019 (COVID-19) epidemic. [ Time Frame: through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Jhankruti F Zaveri, MPH

(713) 745-2645jzaveri@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Bruce F. Sabath

240-476-8938bsabath@mdanderson.org

Principal Investigator:

Bruce F. Sabath

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Aug 10, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-10.